In conclusion, TLR-4 may be a key factor in the development of resistance to 5-FU chemotherapy in colitis-associated CRC, suggesting that the combined use of TLR-4 antagonists and regulation of the intestinal flora may provide potential ideas for further improving CRC treatment. The gene discussed is TLR4; the disease is colitis.